MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.
Epistemonikos ID: 0d286f71c254ac2b098d05395deb0a9f9f3b5517
First added on: Dec 03, 2025